cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-2132Research ArticleОБЗОРЫREVIEWSβ-адреноблокаторы в кардиологической практикеBeta-adrenoblockers in cardiology practiceГарганееваА. А.GarganeevaA. A.

руководитель отделения амбулаторной и профилактической кардиологии

aag@cardio.tsu.ruНИИ кардиологии СО РАМН. ТомскResearch Institute of Cardiology, Siberian Branch, Russian Academy of Medical Sciences. Tomsk20102010201095107114Copyright © Гарганеева А.А., 20102010Гарганеева А.А.Garganeeva A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2132

В статье представлены актуальные и спорные вопросы использования бета-адреноблокаторов (β-АБ) у больных артериальной гипертензией (АГ), ишемической болезнью сердца (ИБС), при сердечной недостаточности (СН), сахарном диабете (СД) и в периоперационном периоде у пациентов, которым выполнялись некардиальные хирургические вмешательства с целью снижения риска сердечно-сосудистых осложнений (ССО). β-АБ являются гетерогенным классом лекарств, различающихся не только по физико-химическим свойствам, но и по степени избирательности действия на разные подвиды адренорецепторов, а также по дополнительным свойствам, в связи с чем, не всегда правомерно говорить о “классэффекте” этих препаратов. Обсуждается целесообразность для подтверждения или опровержения наличия “класс-эффекта” и соответственно равного влияния на прогноз больных с сердечно-сосудистой патологией проведение крупных, независимых, прямых, сравнительных рандомизированных клинических исследований (РКИ) препаратов одного класса.

This article is focused on actual and disputable points of use of beta-blockers for decrease of cardiovascular events in patients with arterial hypertension, ischemic heart disease, heart failure, diabetes mellitus and after non-cardiac surgical operations. Class of beta-blockers is very heterogeneous group of drugs which have different physical and chemical properties, various beta-receptor’s selectivity and additional characteristics. That is why the popular concept of “class-effect” seems not valid for this particular pharmaceutical class. The need for independent direct comparisons of different beta-blockers in randomised controlled trials is discussed.

сердечно-сосудистые заболеваниябета-адреноблокаторы“класс-эффект”влияние на прогнозcardiovascular diseasebeta-adrenoblockersclass effectinfluence on prognosisReferencesExpert consensus document on beta-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Eur Heart J 2004; 25: 1341-62. doi:10.1016/j.ehj.2004.06.002.Expert consensus document on beta-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J et al. Eur Heart J 2004; 25: 1341-62. doi:10.1016/j.ehj.2004.06.002.Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol withdrawal rebound phenomenon: exacerbations of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293: 416-8.Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol withdrawal rebound phenomenon: exacerbations of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293: 416-8.Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 1977; 87: 433-6.Hypersensitivity to adrenergic stimulation after propranolol withdrawal in normal subjects. Ann Intern Med 1977; 87: 433-6.β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247(12): 1707-14.β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247(12): 1707-14.Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6.Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6.www.nobelprize.org; Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116:515-23.www.nobelprize.org; Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988;116:515-23.Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: Издательство “Медпрактика” 1996; 784 стр.Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. М.: Издательство “Медпрактика” 1996; 784 стр.Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71.Sawa M, Harada H. Recent developments in the design of orally bioavailable beta-3-adrenergic receptor agonists. Curr Med Chem 2006; 13(1): 25-37.Sawa M, Harada H. Recent developments in the design of orally bioavailable beta-3-adrenergic receptor agonists. Curr Med Chem 2006; 13(1): 25-37.Opie LH. Drugs for the heart. 7-th edition. Edited by Lionel H. Opie. Publisher Philadelphia, Saunders/Elsevier 2009; 502 p.Opie LH. Drugs for the heart. 7-th edition. Edited by Lionel H. Opie. Publisher Philadelphia, Saunders/Elsevier 2009; 502 p.Maggioni A. Review of the new ESC quidelines for the pharmacological management of chronic heart failure. Eur Heart J 2005; 7: J15-21.Maggioni A. Review of the new ESC quidelines for the pharmacological management of chronic heart failure. Eur Heart J 2005; 7: J15-21.Клиническая фармакология лекарственных средств, применяемых при артериальной гипертензии. Учебное пособие для медицинских вузов. Cост. С.В. Мальчикова. — Киров: Кировская ГМА 2007; 90 с.Клиническая фармакология лекарственных средств, применяемых при артериальной гипертензии. Учебное пособие для медицинских вузов. Cост. С.В. Мальчикова. — Киров: Кировская ГМА 2007; 90 с.Харкевич Д.А. Фармакология. Учебник для ВУЗов. М.: ГЭОТАР — Медиа 2005; 736 стр.Харкевич Д.А. Фармакология. Учебник для ВУЗов. М.: ГЭОТАР — Медиа 2005; 736 стр.Streufert S, DePadova A, McGlynn T, et al. Impact of betablockade on complex cognitive functioning. Am Heart J 1988; 116(1Pt2): 311-5.Streufert S, DePadova A, McGlynn T, et al. Impact of betablockade on complex cognitive functioning. Am Heart J 1988; 116(1Pt2): 311-5.Khan Gabriel M. Cardiac drug therapy. 7-th Edition, 2007. 420 p. Humana Press Inc.:31.Khan Gabriel M. Cardiac drug therapy. 7-th Edition, 2007. 420 p. Humana Press Inc.:31.Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 39(5): 445-56.Soriano JB, Hoes AW, Meems L, Grobbee DE. Increased survival with beta-blockers: importance of ancillary properties. Prog Cardiovasc Dis 1997; 39(5): 445-56.Egilok Retard. Clinical Study Reports. Lambda Ther. Res. Ltd. Report 2004; N031-04:81.Egilok Retard. Clinical Study Reports. Lambda Ther. Res. Ltd. Report 2004; N031-04:81.Bangalore S, Wild D, Parkar S, et al. Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension: Insights From a Meta-Analysis. JACC 2008; 52(13): 1062-72.Bangalore S, Wild D, Parkar S, et al. Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension: Insights From a Meta-Analysis. JACC 2008; 52(13): 1062-72.MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12.MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12.Dahlof B, Sever PS, Poulter NR, et al. ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Web site: http://www. ascotstudy.co.ukDahlof B, Sever PS, Poulter NR, et al. ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the AngloScandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906. Web site: http://www. ascotstudy.co.ukPepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290(21): 2805-16.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003 Dec 3; 290(21): 2805-16.Zanchetti A, Gene Bond M, Hennig M, et al. on behalf of the ELSA investigators. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis. Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial. Circulation 2002; 106: 2422-7. Published online before print October 21, 2002, doi: 10.1161/01.CIR.0000039288.86470.DD.Zanchetti A, Gene Bond M, Hennig M, et al. on behalf of the ELSA investigators. Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis. Principal Results of the European Lacidipine Study on Atherosclerosis (ELSA), a Randomized, Double-Blind, Long-Term Trial. Circulation 2002; 106: 2422-7. Published online before print October 21, 2002, doi: 10.1161/01.CIR.0000039288.86470.DD.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.New BHS-NICE guidelines (Jun 2006). Prescription guidelines in cardiology. Editions Frison-Roche 2006.New BHS-NICE guidelines (Jun 2006). Prescription guidelines in cardiology. Editions Frison-Roche 2006.Wiysonge CSU, Bradley HA, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003. DOI: 10.1002/14651858.Wiysonge CSU, Bradley HA, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002003. DOI: 10.1002/14651858.Cockcroft J.R. Atenolol is dead: long live beta-blockade. JACC 2009; 53; 2102 doi:10.1016/j.jacc.2008.12.076.Cockcroft J.R. Atenolol is dead: long live beta-blockade. JACC 2009; 53; 2102 doi:10.1016/j.jacc.2008.12.076.Dhakam Z, Yasmin, McEniery C, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26(2): 351-6.Dhakam Z, Yasmin, McEniery C, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26(2): 351-6.Маколкин В.И. Бета-блокаторы остаются препаратами выбора при лечении артериальной гипертонии. Сердце 2009; 8(3(47)):138-9.Маколкин В.И. Бета-блокаторы остаются препаратами выбора при лечении артериальной гипертонии. Сердце 2009; 8(3(47)):138-9.Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-41.Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens 2006; 24: 2131-41.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Москва, 2008. Кардиоваск тер профил 2008;7(6):. Приложение 2:18-9.Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Москва, 2008. Кардиоваск тер профил 2008;7(6):. Приложение 2:18-9.Hollenberg NK. The Role of β-Blockers as a Cornerstone of Cardiovascular Therapy. Am J Hypertens 2005; 18(12), Part 2: 165S-8.Hollenberg NK. The Role of β-Blockers as a Cornerstone of Cardiovascular Therapy. Am J Hypertens 2005; 18(12), Part 2: 165S-8.Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991; 17: 579-88.Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study. Hypertension 1991; 17: 579-88.Khan N, McAlister FA. Re-examining the efficacy of betablockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-42.Khan N, McAlister FA. Re-examining the efficacy of betablockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737-42.Оганов Р.Г., Перова Н.В., Щельцина Н.В. и др. Проявления метаболического синдрома при сочетании артериальной гипертонии с отдельными факторами коронарного риска. Кардиология 2005; 7: 27-33.Оганов Р.Г., Перова Н.В., Щельцина Н.В. и др. Проявления метаболического синдрома при сочетании артериальной гипертонии с отдельными факторами коронарного риска. Кардиология 2005; 7: 27-33.Sipahi I, Tuzcu EM, Wolski K, et al. Analysis of 4 Intravascular Ultrasonography Trials. Ann Intern Med 2007; 147: 10-8.Sipahi I, Tuzcu EM, Wolski K, et al. Analysis of 4 Intravascular Ultrasonography Trials. Ann Intern Med 2007; 147: 10-8.Goldberger J, Cain M, Hohnloser S, et al. American Heart Association/American College of Cardiology and Council on Epidemiology and Prevention on Clinical Cardiology Committee on Electrocardiography and Arrhythmias Death: A Scientific Statement From the American Heart Association Council Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk. JACC 2008; 52: 1179-99. http://content.onlinejacc.org/cgi/content/full/52/14/1179.Goldberger J, Cain M, Hohnloser S, et al. American Heart Association/American College of Cardiology and Council on Epidemiology and Prevention on Clinical Cardiology Committee on Electrocardiography and Arrhythmias Death: A Scientific Statement From the American Heart Association Council Stratification Techniques for Identifying Patients at Risk for Sudden Cardiac Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk. JACC 2008; 52: 1179-99. http://content.onlinejacc.org/cgi/content/full/52/14/1179.Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7.Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36.Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975; 37: 1022-36.Stevenson LW. Beta-Blockers for Stable Heart Failure. N Engl J Med 2002; 346(18): 1346-7.Stevenson LW. Beta-Blockers for Stable Heart Failure. N Engl J Med 2002; 346(18): 1346-7.Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. JACC 2004; 43(3): 317-27.Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. JACC 2004; 43(3): 317-27.Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and heart failure with preserved ejection fraction. N Engl Med 2006; 355(3): 251-9.Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and heart failure with preserved ejection fraction. N Engl Med 2006; 355(3): 251-9.Кастаян А.А., Неласов Н.Ю., Каплина Е.В. и др. Бетаблокаторы при хронической сердечной недостаточности с неизмененной фракцией выброса. Серд недостат 2008; 4(48):191-3.Кастаян А.А., Неласов Н.Ю., Каплина Е.В. и др. Бетаблокаторы при хронической сердечной недостаточности с неизмененной фракцией выброса. Серд недостат 2008; 4(48):191-3.Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. (Letter). Lancet 2003; 362: 1077-8.Hjalmarson A, Waagstein F. COMET: a proposed mechanism of action to explain the results and concerns about dose. (Letter). Lancet 2003; 362: 1077-8.Hjalmarson A, Herlitz J, Malek L, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; ii: 823-7.Hjalmarson A, Herlitz J, Malek L, et al. Effect on mortality of metoprolol in acute myocardial infarction. Lancet 1981; ii: 823-7.Ahrens W, Hagemeier C, Mühlbauer B, et al. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf 2007; 16(12): 1298-307.Ahrens W, Hagemeier C, Mühlbauer B, et al. Hospitalization rates of generic metoprolol compared with the original beta-blocker in an epidemiological database study. Pharmacoepidemiol Drug Saf 2007; 16(12): 1298-307.Boersma E, Kertai M, Schouten O, et al. Perioperative cardiovascular mortalityin noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 2005; 118: 1134-41.Boersma E, Kertai M, Schouten O, et al. Perioperative cardiovascular mortalityin noncardiac surgery: validation of the Lee cardiac risk index. Am J Med 2005; 118: 1134-41.Poldermans D, Bax J, Kertai M, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-51.Poldermans D, Bax J, Kertai M, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 2003; 107: 1848-51.Devereaux P, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomized controlled trial. Lancet 2008; 371: 1839-47.Devereaux P, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomized controlled trial. Lancet 2008; 371: 1839-47.The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769-812.The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769-812.Ryde´n L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal doi:10.1093/ eurheartj/ehl261.Ryde´n L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal doi:10.1093/ eurheartj/ehl261.База данных аналитической компании “Фармэксперт”. 1 квартал 2010 года. http://int.pharmexpert.ru/База данных аналитической компании “Фармэксперт”. 1 квартал 2010 года. http://int.pharmexpert.ru/

The authors declare that there are no conflicts of interest present.